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ABSTRACT
Hensley, Amber Lee. M.S. Department of Neuroscience, Cell Biology, and Physiology,
Wright State University, 2016. The Use of Doublecortin to Visualize the Effects of
Pharmacological Treatment on Neurogenesis and Functional Recovery after Stroke.
Ischemic strokes account for 87% of all strokes and can have debilitating effects on
language, sensory, and motor skills. Currently, tPA is the only medication approved by the
FDA for the treatment of ischemic stroke, but the window of time to administer the drug is
very small. In this thesis, we investigate the use of a simvastatin and fluoxetine drug
combination (FS) as a possible alternative treatment for ischemic stroke victims. To analyze
the effects of FS on neurogenesis and functional recovery, we utilize the Montoya Staircase
and quantify the amount of neurogenesis using doublecortin.
Although the results of this study show that the drug treatment did not produce the
significant increase in neurogenesis when comparing the control with the drug-treated
animals as we had hoped for, nor did it translate to an increase in functional recovery, there
was significantly more neurogenesis in the right hemisphere in the anterior and middle region
of the subventricular zone (SVZ) of the FS rats than the left. This tells us that the drug
treatment did produce a significant amount of neurogenesis in the SVZ, but further work
needs to be done to better understand how the FS drug treatment effects neurogenesis and
functional recovery. There may be an optimal window of time and dosage that will lead to a
greater significance in recovery and higher levels of neurogenesis. This could open the door
for a better treatment option to increase the quality of life for ischemic stroke patients.
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I.

INTRODUCTION

STROKE RESEARCH
Stroke is the fifth leading cause of death for Americans, and each year
approximately 130,000 Americans are killed by stroke. That is one out of every 20
deaths, with 66% of those deaths being adults over the age of 65. The cost of health care,
treatment medications, and missed days of work amount to an estimated 34 billion dollars
each year. (CDC, 2015).

Types of Stroke
There are two main different types of stroke, hemorrhagic and ischemic. There is
also a transient stroke, which is a form of ischemic stroke. They are discussed in greater
detail below.

Hemorrhagic
Hemorrhagic stroke results from the rupturing of weak or damaged blood vessels
that bleed into the brain. There are two types of vessels that can lead to hemorrhagic
bleeding, an aneurysm and arteriovenous malformation. Aneurysms are vessels that
balloon out due to fragile vessel walls, which break when they become too thin.
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Arteriovenous malformation are bundles of blood vessels that are formed abnormally,
which are more delicate and prone to rupturing (The American Heart Association,
2015a).

Ischemic
Ischemic strokes account for 87% of all stroke victims. Ischemic strokes occur
when the vessels in the brain become blocked or occluded. The primary cause for the
occlusion is atherosclerosis, which is when fatty deposits line the blood vessel walls and
impedes the flow of blood. This impedance of flow can be caused by either a cerebral
thrombosis or cerebral embolism. Cerebral thrombosis occurs when a blood clot develops
in the narrowed walls of the blood vessels of the brain. Cerebral embolism is when a
blood clot from another location in the circulatory system travels to the brain and then
becomes lodged in the narrowed vessel (The American Heart Association, 2015b).

Transient Ischemic Attack (TIA)
Lastly, another form of stroke is the transient ischemic attack or TIA. This is very
similar to an ischemic stroke, except the clot that blocks the blood vessel in the brain is
temporary or transient. This ‘attack’ differs from a stroke, because the blood clot is
broken up before it causes permanent damage in the brain. This typically only lasts
roughly five minutes, but it is a precursor to a larger or full-fledged stroke and should be
treated as such (The American Heart Association, 2012).
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NEUROGENESIS
Neurogenesis is the birth of new neurons in the brain. It was long believed that
this only occurred in the prenatal and developing brain, and the mature brains of adults
could not actively give birth to new neurons until Joseph Altman’s work in the 1960’s
lead to the discovery of adult neurogenesis (Altman, 1963; Saaltink & Vreugdenhil,
2014). Neurogenesis after ischemic stroke aids in the repair of damaged tissue from the
lack of blood flow. In turn, if the tissue can be repaired, the function coordinating to that
tissue may also be restored.
Neurogenesis is commonly localized in two locations in the adult brain, the
subgranluar zone (SGZ) of the dentate gyrus in the hippocampus and the subventricular
zone (SVZ). The SVZ will be the focus of this study because it is the location
corresponding with post-stroke neurogenesis. This can be deduced from the deficits that
result from the majority of acute strokes; language, sensory, and motor skills. These
functions are largely affected by a stroke and do not originate from the hippocampus
(Carmichael, 2010; R. L. Zhang, Zhang, & Chopp, 2008). Some stroke vitims do see
damage to their hippocampus, but the forelimb motor cortex was targeted for this study,
so a deficit in motor skills was analyzed. When visualizing neurogenesis in the SVZ, we
look at levels in the anterior, middle, and posterior regions of each hemisphere. The three
different regions can be visualized in Figure 1.
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Figure 1: From top to bottom, a series of images from one hemisphere of the anterior,
middle, and posterior subventricular zone from the rat brain atlas.
4

Stress Effects on Neurogenesis
Adult neurogenesis is greatly affected by hormones released during stress. The
release of glucocorticoids during stress stimulates a decrease in the rate of stem or
progenitor cell proliferation and can even cause tissue atrophy in the adult hippocampus
(Mirescu & Gould, 2006; Warner-Schmidt & Duman, 2006). Due to our interest in
neurogenesis, it is of great importance that stress be reduced to a minimum so the effect
of the drug combination can be accurately quantified. To achieve a low-stress
environment during drug administration we used a voluntary oral method used in
previous work. This voluntary oral method of drug delivery involved placing the powered
drug in a ball of sugar cookie dough. If the animal was in the control group, they received
the dough by itself. This method resulted in significantly lower stress levels and higher
results of consistent ingestion (A. Corbett, McGowin, Sieber, Flannery, & Sibbitt, 2012).

Neurogenesis Labeling
Neurogenesis begins with progenitor cells located outside the hippocampus, in the
SGZ of the dentate gyrus. Here, they proliferate, differentiate, and then become new
neurons. Each phase of neurogenesis expresses different markers, so it is important to
select the proper marker to monitor the stage of neurogenesis we wish to see (von Bohlen
und Halbach, 2007).
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Use of Doublecortin
Doublecortin, or DCX, is a microtubule-associated protein (MAP) that is
expressed in both the cell body and processes of migrating neurons. Particularly, it is
present in developing as well as mature rodent brains (Vellema, Hertel, Urbanus, Van der
Linden, & Gahr, 2014) DCX expression is specific for newly formed neurons, because
the doublecortin-positive cells express antigens for early neurons (von Bohlen und
Halbach, 2007).

Why not Bromodeoxyuridine?
Bromodeoxyuridine (BrdU) is an analog of thymidine that integrates DNA of
dividing cells during the synthesis, or S-phase, of the cell cycle. Because of this, BrdU is
traditionally used for birth dating and monitoring cell proliferation, but it has been used
more recently as an in-situ marker for neurogenesis (Taupin, 2007). BrdU only labels
cells during DNA replication and for approximately 24 hours after injection, while DCX
labels new neurons from a two-week timeframe (Balthazart & Ball, 2014). The main
problem with this characteristic is that BrdU can give false positives when looking at
tissue after trauma. There is natural DNA repair after stroke induction that will be labeled
by BdrU, which is not neurogenesis, whereas doublecortin tags only the migrating
neurons of repair (Nowakowski & Hayes, 2000).
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STROKE INDUCTION
Middle Cerebral Arterial Occlusion Model
The middle cerebral arterial occlusion or MCAO model was not used in this study
because we utilized older rats. Occlusion of the middle cerebral artery is a very common
method of inducing stroke in younger rats, but it creates more damage than desired for
this research. This method typically involved surgical insertion and removal of clips and
sutures and the older rats in this study would not have been able to survive a larger
stroke. To create less damage, endothelin-1 was used to induce stroke. Endothelin-1 is a
powerful vasoconstrictor that allows the blood flow to be cut off from the targeted area
for a length of approximately 12 hours before it wears off and blood flow continues. This
is very similar to how ischemic strokes present in the human brain; the clot breaks up
naturally, but the blood flow is restricted long enough to damage the surrounding tissue.
This caused a smaller and more targeted restriction of blood flow to supply greater
control over the damage. This also allowed for a more targeted stroke area with a less
invasive surgery (Nikolova et al., 2009).

SELECTION OF TREATMENT DRUGS
Standard Treatment
The standard treatment for ischemic stroke patients is the administration of the
drug tissue plasminogen activator or tPA. This is the only drug approved by the FDA for
the treatment of ischemic stroke and the window of time to administer the drug is very
small (Rivera-Bou, Wanda; Cavanas, Jose; Villanueva, 2015). Research shows that stroke
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victims have a window of three hours after the onset of their symptoms to receive tPA if
they hope to see improvement over the next three months. If the drug is administered
after the three-hour window, the risk of causing secondary bleeding in the brain increases
(Hacke et al., 2004). There are successful treatments that reestablish brain perfusion and
minimize the probability of a recurrent stroke, but there is no treatment proven to
promote neurological repair from the damage induced by stroke (Mead et al., 2013).

Fluoxetine
Fluoxetine is a selective serotonin reuptake inhibitor or SSRI, which is highly
prescribed to treat depression. More recently, fluoxetine is being investigated as a
possible treatment drug for ischemic stroke patients, because it has been found to
“improve motor recovery and reduce dependency after stroke when given to people
without depression” (Chollet et al., 2011). This is correlated with the connection between
stress and neurogenesis discussed earlier, in which administration of a chronic
antidepressant treatment could up-regulate neurogenesis, and possibly block or reverse
the atrophy and damage caused by stress or the damage from a stroke (Warner-Schmidt
& Duman, 2006). Fluoxetine given on a daily basis one week after stroke can increase the
number of proliferating neurons in the SVZ (Xiaoyu Sun et al., 2015, 2016).
In a similar study, hippocampal neurogenesis was disrupted after the onset of
ischemic stroke to analyze the ability of fluoxetine to stimulate neurogenesis in the brain.
This disruption ceased the beneficial effect of fluoxetine on cognitive impairment poststroke. This suggests that fluoxetine treatment after an ischemic event can improve
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spatial cognitive function recovery via neurogenesis in the subgranular zone as well (Li et
al., 2009).

Simvastatin
Simvastatin is a statin, also known as an HMGR inhibitor. HMG-CoA (3hydroxy-3-methylglutaryl-coenzyme A) reductase, or HMGR, catalyzes the committed
step in cholesterol biosynthesis. Due to the inhibition of this synthesis, simvastatin
effectively lowers blood cholesterol levels and is commonly prescribed in the treatment
of hypercholesterolemia and stroke prevention. In addition to lowering cholesterol,
simvastatin promotes the nitric oxide mediated stimulation of new blood vessel growth
(Istvan & Deisenhofer, 2001). When administered after stroke, it has been shown to
augment functional outcome and stimulate neurogenesis (Chen et al., 2003).

Drug combination
We wanted to further investigate the possibility of using fluoxetine and
simvastatin as a drug combination that can be used as a treatment to stimulate
neurogenesis and repair functional deficits after an ischemic stroke. We used a
combination of 5 mg/kg of fluoxetine and 1 mg/kg of simvastatin; in which the dosage
was chosen based on similar dosage recommendations given to humans and scaled-down
to the rat model.
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HYPOTHESIS
We believe the simvastatin and fluoxetine drug combination will significantly
increase functional recovery by stimulating neurogenesis when administered 6-12 hours
after ischemic stroke.
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II. MATERIALS AND METHODS
All research discussed in this document was performed in accordance with protocols
approved by the Wright State University Institutional Animal Care and Use Committee
(IACUC).

EXPERIMENTAL OVERVIEW
Research Animals
Sprague Dawley outbred retired breeder rats were chosen for this experiment. The
female Sprague Dawley was selected due to the size needed to fit into the Montoya
Staircase training apparatus; the males were too large to accommodate. The rats ranged
from 10 to 12 months in age and were ordered from Harlan Laboratories in Indianapolis,
Indiana. The adults were selected to mirror the physiological development of a typical
human stroke patient. Rat pups were not of the correct neurological maturity to make
accurate comparisons (Sengupta, 2013).
The rats were housed in separate, numbered cages to aid in accurate data
collection. The cages were 952cm2 hanging shoeboxes with wire lids and ¼ - ½ inch
depth of Harlan Teklad Sani-chip bedding. All rats were kept in a room on a light
schedule of 12 hours on and 12 hours off with a room temperature of 23-24°C. The food
given throughout the entire experiment was Harlan Teklad rodent chow 8640. The rats
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were placed on a restrictive diet during the training to encourage retrieval of the reward
pellets. To determine the amount of food to be considered ‘restricted’ the amount of ad
lib food eaten over a two-day period was calculated. They were given a weighed amount
of food upon arrival and it was left in their cages for two days. After the two days, the
remaining food was weighed, and subtracted from the initial weight to determine the ad
lib food eaten. The restricted amount of food was calculated to 85% of the weighed
amount of food that was eaten the first two days. The rats’ weight loss was closely
monitored to maintain a healthy size. They were weighed prior to administration of the
restricted diet and then subsequently weighed every three days until the completion of
training. The rats then fasted overnight before the training began and were then fed their
restricted diet after training session was completed each day. If the loss of weight rose to
10% of the original, the diet was increased to counterbalance that loss.

Montoya Staircase
The Montoya Staircase is a test developed by Montoya to assess the reaching
capability of each forelimb. The ‘staircase’, as seen in Figure 2, is a clear Plexiglas box
with a removable raised platform with seven bilateral graded steps. Each step has a well
in which food pellets may be placed. This device allows the rat to step into the box on the
platform and reach with the forelimbs into the wells to grasp the food. The steps allow
for a gradual increase in difficulty of reaching the items in the wells due to an increase in
the forelimb extension and grasping that takes place as the steps reach the bottom of the
box (Montoya, Campbell-Hope, Pemberton, & Dunnett, 1991). Plain and maple extract
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painted sucrose pellets (Bioserv 45 mg dustless precision pellets) were used in this study
as an incentive to train in the staircase. Using three pellets per well, a total of 21 pellets
were placed on each side of the platform.
Each rat was trained in the Montoya Staircase on a daily basis during the dark
cycle for 1.5 weeks prior to surgery. Three staircases were placed side-by-side and three
rats (one in each staircase) were placed into them to allow for more rats to be tested in a
shorter amount of time. They were placed in the staircase for 15 minutes and then
returned to their cages. The number of pellets taken from the wells was recorded and the
highest values were noted as the pre-stroke number of pellets taken. Any rat that did not
take more than nine out of the 21 pellets was excluded from the analysis. These rats were
considered to have not taken to the training or did not like the sucrose pellets as a reward
and could not be reliable to collect data from post-surgery because their deficit could not
be reliably quantified. After surgery was performed the animals were retested on the
Staircase to determine their initial functional deficit (post-stroke days 3-5) and then their
functional recovery (tested every thirty days).
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(Lafayette Instrument Company, 2015)
Figure 2: A rat performing the functional testing in the Montoya Staircase.
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INDUCTION OF STROKE
Summary
Stroke was induced to the right hemisphere of all rats in this study. This induction
caused impairment to the left forelimb, or the contralateral limb. The stroke was induced
via two injections of a vasoconstrictor, endothelin-1, while under anesthesia.

Prior to Stroke Induction
The rats’ cages were taken out of their room individually and brought into the
operation room during surgery. Once taken out of their cage, the empty cage was placed
onto a heating pad so it was warm for the rat during recovery. The rat was placed into a
chamber that administered 5% isoflurane gas. Once the rat was sedated, it was taken out
of the chamber and the top of the head was shaved. Puralube eye ointment was applied to
the eyes to keep them from drying out and the head was sterilized with povidone-iodine,
ethanol, and then povidone-iodine again. They were then laid on top of a heating pad to
keep their body temperature at a safe level during the procedure and placed in the
stereotactic apparatus to stabilize their head. A specialized gas mask was attached to the
rat’s nose to continually administer a 2-3% isoflurane gas during surgery. The rate of
respiration, observation of color of the flesh, as well as a foot-pinch withdrawal reflex
method was used to monitor the effectiveness of the anesthesia and the health of the rats
during surgery.
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Stroke Induction Operation
A straight line was cut down the midline of the skull using scissors and
bupivacaine was applied to the lacerated skin. The location of bregma was found and
identified with a fine point marker and aligned with a burr bit in a microdrill. The
forelimb motor cortex was located with an atlas and coordinates were used from Bregma
to find the appropriate location. To drill the first hole in the skull, the drill was moved 2.5mm medial-lateral and 0mm anterior-posterior from bregma. The second hole was
drilled 2.5mm medial-lateral and +1.5mm anterior-posterior from bregma. The microdrill
was removed and a Hamilton syringe was inserted into the stereotactic apparatus. The
syringe contained 3µl of endothelin (400pmoles/µl). The endothelin (1.5µl per hole) was
slowly injected into the drill sites at a depth of 2.0mm. After the injections were
administered, the syringe was removed and the skin was sutured. Resorbable sutures were
used and after closure, the site was sterilized again with povidone-iodine.

Post-Stroke Care
A 2ml injection of saline was administered subcutaneously prior to placing the rat
back in its warm cage. After being placed in the cage, the rat was monitored until it woke
up from the anesthesia and began moving normally again. After normal activity was
observed, the rat and its cage were taken back into the room where they were housed, and
the next rat was brought out. All of the rats received moist food on the floor of their cages
for two days after surgery to make sure food was accessible and easy to consume.
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TREATMENT AND TRAINING
Drug Administration
Treatment for the stroke started 6-12 hours post-procedure and lasted for 90 days.
The rats received either the drug/vehicle combination or they just received the vehicle.
The rats that received the vehicle only were in the control group. The drug combination
used in this study contained 1mg/kg of Simvastatin and 5mg/kg of Fluoxetine, also
referred to as FS throughout this paper. This drug combination was selected based on a
previous study which found a 19-fold increase in neurogenesis in ischemic rats treated
with this drug combination versus controls (A. M. Corbett et al., 2015). This drug combo
was in a powder form and placed into the vehicle. To reduce stress, a 3-4g ball of
Pillsbury sugar cookie dough was the chosen vehicle used to administer the drugs. This
was selected specifically because the rats ate the dough voluntarily and in entirety in a
previous study (A. Corbett et al., 2012). If a rat did happen to refuse the cookie dough 3
or more times, they were removed from the analysis.
There was no additional administration of pain medication after the stroke. This
includes non-steroidal anti-inflammatory drugs as well as analgesic opioids because there
has been research performed that has found that these medications influence neurogenesis
(Ajmone-Cat & Minghetti, 2008).

Post-Operative Montoya Staircase Training
The rats were given three to five days to heal before the functional testing began,
and then the post-operative testing was done after this recovery period to gauge the level
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of deficit caused by the stroke. The number of pellets taken from the wells during this
time was recorded, then divided by their performance with the same paw pre-stroke, to
give us a normalized contralateral function and ipsilateral function. If this quotient was
less than one, then the animal had a functional deficit, which could be determined by
subtracting this value from one. For example, if a rat retrieved 6 pellet post-stroke with
its left paw, but it had retrieved 18 pellets pre-stroke, then its contralateral function would
be 0.33, and the rat would have a 67% deficit in that limb. The rats were again placed in
the staircase at 30, 60, and 90 days post-surgery, to monitor functional recovery. The
exact days on which the rats were tested are as follows: post-stroke days 3 to 5, poststroke days 29 to 31, post-stroke days 59 to 61, and post-stroke days 89 to 91.

EUTHANASIA AND HISTOLOGY
Euthanasia
After 91 days of post-operative study, the rats were euthanized. Each rat was
taken into a room for anesthesia and euthanization separately to minimize trauma and
stress. An overdose of sodium pentobarbital (100mg/kg Euthasol) was given and then
exsanguination was initiated by clamping a catheter allowing phosphate buffered saline
(PBS) flow into the apex of the heart (left ventricle), while cutting the right atria. Saline
was pumped into the left ventricle of the heart while the blood drained from the right
atria. Following approximately 100 ml of PBS infused through the heart, the solution was
switched to 4% paraformaldehyde in PBS and the animal was kept on this solution until
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at least 150 ml had been pumped through the heart. Dissection and removal of the brain
followed and the left hemisphere was marked.

Preservation and Preparation of Brain Slides
Each brain was placed immediately into a solution of four percent
paraformaldehyde in PBS overnight after blocking the brain (cutting it into coronal
sections) and retaining the section, which included the infarct. The following day the
brains were moved into a solution of 30 percent sucrose for a duration of three days. The
brains were taken from the sucrose solution and placed into Optimal Cutting Temperature
compound to a cutting post. A Peltier cooling device on the cryostat machine was used to
freeze the brain and Optimal Cutting Temperature combination. This freezing process
lasted approximately 30 minutes, because the tissue and compound had to reach the same
temperature of the cryostat before the tissue could be sectioned safely. If the sectioning
was completed too quickly, the tissue could be damaged and lost.
The brain was then sectioned into coronal slices measuring 50 µm in thickness
and placed into four labeled vials of solution. The solution in the vials was a phosphate
buffered solution. The tissue was separated into four vials because other experiments
needed to utilize the same tissue from the experiment for a separate analysis. This means
that after the sections are placed in their separate vials, they will each be stained or
marked with a different solution for their specific experiment. The vial of sections used in
this experiment were marked with doublecortin.
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Sectioning
The sectioning was done throughout the entire ventricle area of the brain. Once
the ends of the ventricles were reached, the sections could be prepared for mounting on
slides. The vials were emptied into petri dishes of fresh phosphate buffered solution and
carefully placed on a glass slide with a small paintbrush to minimize any tearing of the
tissue. Up to five sections could be placed onto one slide for mounting. Once the sections
were strategically placed on the slides they were set aside to dry and placed in a slide
holder.

Staining
Once the slices of tissue were dry, they could then be tagged. In this study, a
marker was used instead of a stain. The binding protein doublecortin, DCX, was used to
visualize new neurons at the site of damage. This protein binds to new neurons to mark or
tag the site of neurogenesis. The tissue was blocked with PBS-Tween containing the
serum from the host of the secondary antibody for one hour. The doublecortin antibody
was then added and the vials were left to shake overnight in the cold. The antibody
solution was then removed and the vials were washed with 5 ml of PBS-Tween two times
before putting on the secondary antibody in blocking solution for two hours at room
temperature.
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Microscopy and Image Collection
The slides were analyzed via brightfield microscopy using a 4X objective lens on
Wright State University’s Olympus Epi Fluorescence SPOT Scope with RT color camera.
This equipment is available to Wright State University students through the Microscopy
Core Facility in the Biological Sciences building. The microscopes can be checked out
for chunks of time using the iLab Solutions website.
Once the images were collected via the SPOT microscope, they were pieced
together, or montaged, using Adobe Photoshop. This method was only used when the
images of the stained brain slice were too large to fit into one screen for saving purposes.
When this occurred, multiple images were captured and then overlapped into one large
picture with Adobe Photoshop.

ImageJ Capture for Quantification
The amount of neurogenesis had to be quantified in each section of tissue. To
accomplish this, the software program ImageJ was utilized. The software allows the user
to select the desired area (in this case it is the area of doublecortin marked tissue as seen
in Figure 3) and calculate that area. The program was calibrated to utilize the same scale
as the microscope, 150µm. It then produced an area in mm2 that could then be stored in
Excel to later analyze.
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Calculation of Area from ImageJ
The area of neurogenesis was then calculated using some simple math to represent
the average amount of neurogenesis taking place in each rat. The doublecortin-labeled
tissue was outlined and the threshold was adjusted. Once this was done, the program
created a mask of the original image to include only the labeled tissue. When this mask
was produced, values for the area of this mask were simultaneously placed in a table.
Each value produced from ImageJ per rat was first added together and then averaged to
give an average area of neurogenesis. This number signified the amount of neurogenesis
for one rat.
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Figure 3: Brightfield microscope images of right ventricles from both the control group
and FS-treated group used for DCX analysis in ImageJ. These images were chosen
because their average DCX levels were representative of their respective groups.
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III. RESULTS

ANALYSIS SOFTWARE
Both unpaired t-tests and two-way ANOVAs were performed using GraphPad
Prism version 6.00 for Mac OS X, GraphPad Software, La Jolla California USA,
www.graphpad.com.

MONTOYA STAIRCASE TRAINING ANALYSIS
Weight Analysis
Weight was monitored during the experimental process and documented, as seen
in Table 1. A two-way ANOVA with repeated measures was done on these weights and
the control group was significantly heavier in grams than the drug-treated rats. In Figure
4, the significance between the two groups is seen at the beginning of the experiment and
remains constant throughout the experiment. This means, although there was a significant
difference in weight between the two groups, it happened by chance and was not related
to the administration of the treatment drug.
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Table 1: This table lists the weights in grams of each rat in both groups throughout the
duration of the experiment. Along the left hand column are the numbers assigned to each
rat.
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Figure 4: Graph shows the average rat weights in grams for both the control and FS
groups throughout the duration of the experiment. The control animals were significantly
heavier than the drug-treated group, but this was not related to treatment.
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Functional Analysis
Every rat was trained on the Montoya Staircase for one and a half weeks prior to
stroke induction. The training occurred every day for a duration of 15 minutes per rat
during the nighttime cycle. This training established a baseline for pre-stroke forelimb
function. The sucrose pellets taken by each rat were counted and documented to later
determine the deficit induced by the stroke, as well as to gauge the level of recovery and
possible neurogenesis. If a rat failed to collect at least nine pellets during the initial prestroke training, they were excluded from this study.
After stroke induction, Montoya testing was continued after a three to five day
recovery period to heal. The testing was then repeated at 30-day intervals to observe
functional deficit and recovery. There were some rats that did not show a contralateral
deficit, which means the number of pellets taken after surgery did not change from their
baseline value. If they showed a decrease in both the contralateral and ipsilateral sides
post-stroke, their deficits were bilateral. This information is listed in Table 2.
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Group

Number of Rats

FS-treated
Control

11
11

Did Not Meet
Criteria
1
0

No Contralateral
Deficit
1
5

Bilateral
Deficit
1
2

Table 2: This table summarizes the groups of rats by numbers in each group and the
types of deficits that occurred.
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To establish a post-stroke deficit, the number of sucrose pellets taken from the
wells were divided by their pre-stroke value for both the contralateral and ipsilateral side;
the contralateral side being the left limb and the ipsilateral side being the right limb. This
number was multiplied by 100 to give the percentages seen in the two graphs below
which represent functional recovery based on the pre-stoke functional baseline values.
See Figure 5.
A two-way ANOVA with repeated measures was performed on the contralateral
side. The control group showed a significantly higher percent recovery from the FS
group, p-value of 0.0005, F (3,57) = 6.89 and as time progressed, each training session
showed a significant increase in function, p-value of 0.021, F (1,19) = 6.298. The same
analysis was conducted for the ipsilateral side with no significance seen.
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Montoya Forelimb Mobility Results
Contralateral

Ipsilateral

Figure 5: Results from the Montoya training for the contralateral and ipsilateral
forelimb function between control and FS throughout the experiment based on the prestroke function.
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To further visualize the final functional recovery between the contralateral and
ipsilateral limbs, the daily recovery was calculated by subtracting the percentage of
contralateral and ipsilateral recovery on the current day of training from the percentages
calculated on the first day of training after surgery (Figure 6). This would mean that if a
rat took fewer pellets from the wells on one side during day 60 of Montoya testing than it
did on day 3, a negative value would be calculated for the recovery on that day. A twoway ANOVA with repeated measures resulted in a significant increase in the recovery
over time for the contralateral limb (p-value = 0.029, F (2, 38) = 3.89), but there was no
significance for the ipsilateral recovery.
The final day of Montoya testing occurred on days 89-90. The number of pellets
taken on these days was compared to the number taken prior to stroke induction. The
same values calculated from the first days post-stroke were then subtracted from the
number calculated on the final day as described above to give a total recovery value.
These values were analyzed with a two-way ANOVA, p-value = 0.0099, F (1, 38) = 7.36)
with the contralateral recovery being significantly higher than the ipsilateral recovery.
There was no significance between control and FS groups. See Figure 7.
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Post-Stroke Functional Recovery
Contralateral

Ipsilateral

Figure 6: Contralateral and ipsilateral recovery values based on the deficit 3-5 days
after stroke induction.
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Figure 7: Overall functional recovery analysis from Montoya training on contralateral
and ipsilateral sides

33

ANALYSIS OF DOUBLECORTIN LEVELS
Doublecortin levels were analyzed in ImageJ using the quantitative tool to find
the area of doublecortin-stained tissue in the SVZ. The anterior, middle, and posterior
ventricles of both the left and right hemispheres were all documented. T-tests with
Welch’s correction were run on the subventricular zone to compare the control with the
FS rats, no significance was found between the two groups. When looking at the left and
right hemispheres within both the control and FS-treated rats, there was significantly
more doublecortin in the right hemisphere of the anterior (p = 0.047) and middle (p =
0.034) regions of the FS-treated rats but not the control. To compare the variances, the Ftest was completed and showed the anterior region to be non significant, while the middle
region showed significance with a p-value of 0.0007. There was no significance between
the two hemispheres in the posterior region. See Figures 8-10.
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Doublecortin Levels in the Anterior SVZ

Control vs FS

Right and Left Hemispheres
of the FS Group ONLY

Figure 8: On the top an analysis of doublecortin levels in the anterior SVZ for control
and FS groups, no significance, and on the bottom an analysis of doublecortin levels in
the right and left anterior hemispheres for the FS group, p = 0.047.
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Doublecortin Levels in the Middle SVZ

Control vs FS

Right and Left Hemispheres
of the FS Group ONLY

Figure 9: On the top an analysis of doublecortin levels in the middle SVZ for control and
FS groups, no significance, and on the bottom an analysis of doublecortin levels in the
right and left middle hemispheres for the FS group, p = 0.034.
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Doublecortin Levels in the Posterior SVZ

Control vs FS

Right and Left Hemispheres
of the FS Group ONLY

Figure 10: On the top an analysis of doublecortin levels in the posterior SVZ for control
and FS groups and on the bottom an analysis of doublecortin levels in the right and left
posterior hemispheres for the FS group with no significance in either posterior region.
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The average areas (in mm2) for each rat are shown in Tables 3 and 4. The control
animals are listed first, followed by the FS-treated animals. The number of coronal slices
per region and hemisphere are listed beside their respective position. The areas of these
slices were averaged to get the value for each location in the brain per rat. The numbers
in the colored boxes are the outlier values that were excluded from the graph in Figure
12, labeled “WITHOUT outliers”. Theses outlier values (8 values total) were excluded
based on the results from the ROUT method outlier test in Prism. This exclusion of
outliers was done to assume a normalized sample size out of our data points.
The right and left hemispheres were separately analyzed in both the control and
FS-treated group by regions in the SVZ; anterior, middle, and posterior, respectively. See
Figure 11. Only the left hemisphere showed any significance. Using a two-way ANOVA,
the control showed a significantly higher average area of doublecortin levels than the FStreated group in the left hemisphere, p-value 0.048, F (1, 58) = 4.09.
The same analysis was completed for the values minus the outliers. A total of 8
values were excluded when plotting without the outliers. In this analysis, the left
hemisphere showed no significance while the right hemisphere showed a significance
between the regions, p-value = 0.0016, F (2,51) = 7.360. This can be seen in Figure 12.
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RAT #
603
Control

AVERAGES
ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

606
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

608
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

613
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

614
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

618
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

625
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

628
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

629
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

631
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

637
Control

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

LEFT
0.03735326
0.03164511
0.02760438
0.03220092
LEFT
0.04038861
0.02260558
0.01693666
0.02664362
LEFT
0.02937307
0.02443037
0.02267387
0.02549244
LEFT
0.03160591
0.02784725
0.02346726
0.02764014
LEFT
0.01242889
0.01106912
0.01174901
LEFT
0.04063172
0.02978225
0.01316601
0.02785999
LEFT
0.03662603
0.09287597
0.04093765
0.05681322
LEFT
0.01488834
0.00956233
0.01909352
0.01451473
LEFT
0.03256098
0.03922494
0.01832268
0.03003620
LEFT
0.03144769
0.03677951
0.03411360
LEFT
0.02089958
0.01136430
0.02235093
0.01820494

# Slices
3
3
3
9
# Slices
3
3
2
8
# Slices
3
4
3
10
# Slices
3
5
3
11
# Slices
1
3
4
# Slices
8
5
2
15
# Slices
4
4
2
10
# Slices
5
2
2
9
# Slices
4
4
3
11
# Slices
3
3
6
# Slices
4
4
3
11

RIGHT
0.05383746
0.02626483
0.02063528
0.03357919
RIGHT
0.02732432
0.01361762
0.00828670
0.01640955
RIGHT
0.04549606
0.04903886
0.03873338
0.04442277
RIGHT
0.03998424
0.02682243
0.02530316
0.03070328
RIGHT
0.02584960
0.01576016
0.02080488
RIGHT
0.03435414
0.02584754
0.01433084
0.02484417
RIGHT
0.03979253
0.17769732
0.16611275
0.12786753
RIGHT
0.01638286
0.00806125
0.01456754
0.01300388
RIGHT
0.02832518
0.01150473
0.00541464
0.01508152
RIGHT
0.02605811
0.02223070
0.02414441
RIGHT
0.02666406
0.01796227
0.04642183
0.03034939

# Slices
3
3
3
9
# Slices
3
3
2
8
# Slices
3
4
3
10
# Slices
3
5
3
11
# Slices
1
3
4
# Slices
8
5
2
15
# Slices
4
4
2
10
# Slices
5
2
2
9
# Slices
4
4
3
11
# Slices
3
3
6
# Slices
4
4
3
11

Region AVE
0.04559536
0.02895497
0.02411983
Region AVE
0.03385646
0.01811160
0.01261168
Region AVE
0.03743457
0.03673462
0.03070363
Region AVE
0.03579508
0.02733484
0.02438521
Region AVE
0.01913925
0.01341464
Region AVE
0.03749293
0.02781489
0.01374843
Region AVE
0.03820928
0.13528664
0.10352520
Region AVE
0.01563560
0.00881179
0.01683053
Region AVE
0.03044308
0.02536484
0.01186866
Region AVE
0.02875290
0.02950511
Region AVE
0.02378182
0.01466329
0.03438638

Table 3: This table shows all the average measurements of doublecortin levels in the
control rats. The number of coronal slices included in each average is listed beside the
average. The colored values were the outlier values determined in Prism.
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RAT #
601
FS

AVERAGES
ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

602
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

605
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

609
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

612
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

615
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

616
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

619
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

620
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

626
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

633
FS

ANTERIOR
MIDDLE
POSTERIOR
Hemisphere AVG

LEFT
0.03262172
0.03831530
0.04378244
0.03823982
LEFT
0.02705986
0.01095186
0.02992129
0.02264434
LEFT
0.01739784
0.00951623
0.00766219

0.01152542
LEFT
0.02634832
0.02559469
0.02103878
0.02432726
LEFT
0.02210068
0.01405449
0.01712889
0.01776136
LEFT
0.01692360
0.03448225
0.02286474
0.02475686
LEFT
0.02223240
0.00726406
0.02576076
0.01841907
LEFT
0.02054480
0.01643758
0.00797510
0.01498583
LEFT
0.03027532
0.01683262
0.00364878
0.01691891
LEFT
0.02790606
0.01284234
0.01641441
0.01905427
LEFT
0.03752320
0.02135801
0.01648662
0.02512261

# Slices
5
3
3
11
# Slices
3
3
3
9
# Slices
4
3
3
10
# Slices
3
6
3
12
# Slices
4
4
2
10
# Slices
1
4
1
6
# Slices
3
3
3
9
# Slices
3
4
2
9
# Slices
3
3
3
9
# Slices
2
4
4
10
# Slices
4
4
4
12

RIGHT
0.04666116
0.08309123
0.01552642
0.04842627
RIGHT
0.02806543
0.02334173
0.00831897
0.01990871
RIGHT
0.02080751
0.01805039
0.01644610

0.01843467
RIGHT
0.03449972
0.07794316
0.06082887
0.05775725
RIGHT
0.02927987
0.10702167
0.01492921
0.05041025
RIGHT
0.04926915
0.06951155
0.02120674
0.04666248
RIGHT
0.02631876
0.01504446
0.01132916
0.01756412
RIGHT
0.02194684
0.01557322
0.01361367
0.01704458
RIGHT
0.03703713
0.01173403
0.01253245
0.02043454
RIGHT
0.03853209
0.02424780
0.01597884
0.02625291
RIGHT
0.02863007
0.04322422
0.06369257
0.04518228

# Slices
5
3
3
11
# Slices
3
3
3
9
# Slices
4
3
3
10
# Slices
3
6
3
12
# Slices
4
4
2
10
# Slices
1
4
1
6
# Slices
3
3
3
9
# Slices
3
4
2
9
# Slices
3
3
2
8
# Slices
2
4
4
10
# Slices
4
4
4
12

Region AVE
0.03964144
0.06070327
0.02965443
Region AVE
0.02756264
0.01714680
0.01912013
Region AVE
0.01910267
0.01378331
0.01205415
Region AVE
0.03042402
0.05176893
0.04093382
Region AVE
0.02569028
0.06053808
0.01602905
Region AVE
0.03309637
0.05199690
0.02203574
Region AVE
0.02427558
0.01115426
0.01854496
Region AVE
0.02124582
0.01600540
0.01079438
Region AVE
0.03365622
0.01428333
0.00809062
Region AVE
0.03321907
0.01854507
0.01619663
Region AVE
0.03307663
0.03229111
0.04008960

Table 4: This table shows all the average measurements of doublecortin levels in the FStreated rats. The number of coronal slices included in each average is listed beside the
average. The colored values were the outlier values determined in Prism.
40

Doublecortin Levels of
Right and Left Hemispheres
RIGHT Hemisphere

LEFT Hemisphere

Figure 11: The average area of doublecortin was analyzed by group and region in the
left and right hemispheres, respectively. A significantly higher area of DCX was found in
the left hemisphere of the control group than the FS group p = 0.048.
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Doublecortin Levels of
Right and Left Hemispheres
WITHOUT Outliers
RIGHT Hemisphere

LEFT Hemisphere

Figure 12: The average area of doublecortin was analyzed after excluding the outlying
areas seen in tables by group and region in the left and right hemispheres, respectively. A
significance between the regions was found p = 0.0016.
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IV. DISCUSSION

FINDINGS
This study found no significance in the functional recovery between the control
and drug-treated animals, though both groups did show a significant increase in
contralateral limb function as the experiment progressed. Neurogenesis was not found to
be significantly higher in the fluoxetine and simvastatin-treated group than the control
animals. There was a significantly higher area of neurogenesis in the anterior and middle
subventricular zone of the stroke-damaged right hemisphere than the left hemisphere
when the drug-treated group was analyzed separately from the control group, which did
not show this same significance.

Functional Recovery
Both the control group and the FS-treated rats showed a consistent and significant
increase in functional recovery of their contralateral forelimb every 30-days during
Montoya testing. This means that both groups showed a significant improvement in the
stroke-damaged forelimb throughout the duration of the experiment, but they were not
significantly different from each other (see Figure 6). This could be because it has been
shown that small infarcts induced via endothelin-1 have enhanced neurogenesis in the
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SVZ in adult mice without pharmacological intervention (Wang, Jin, & Greenberg,
2007). It is possible that the effects of the drugs were not high enough for us to tell the
difference between the natural recovery and the treatment-induced recovery.
The drug-treated rats showed a significantly lower contralateral forelimb mobility
than the control group (see Figure 5). Although the FS group displayed significantly
lower contralateral forelimb functional recovery, they did show a higher recovery rate
from their initial post-stroke deficit, though not significant. This means that the early
administration of the drugs may have caused more damage after the stroke, but it did
result in a greater, though insignificant, recovery than the control group. In fact, in a
parallel study, it was found that earlier administration of the drug combination (6-12
hours post-stroke) resulted in not only a larger infarct size than had previously been seen
when this drug treatment was delivered beginning 20-26 hours after stroke induction, but
in some cases, secondary hemorrhagic stroke was observed. Images of the secondary
hemorrhagic stroke from this same study can be visualized in Figure 13 (Balch et al.,
2015; Ragas et al., 2015).
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Figure 13: Image A shows a control animal from the 6-12 hour administration time study
with the infarct area outlined. Image B shows an FS-treated animal from the 6-12 hour
administration time study with infarct and secondary hemhorragic damage outlined.
Image C is a control animal from the 20-26 hour drug administration study with infarct
outlined. Image D is the FS-treated animal from the 20-26 hour administration time study
with infarct outlined. Figure from work by Maria Balch et al.
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Possible Explanations for Increase in Functional Recovery
We saw an increase in contralateral functional recovery in all of our research
animals at each 30-day Montoya testing for the duration of our study, with the 90-day
analysis being the highest. We looked specifically at neurogenesis in this study, but there
are other factors that contribute to functional recovery after ischemic stroke.
Angiogenesis and neuroplasticity also play major roles in increasing functional
recovery. Neuroplasticity is the ability of the brain to alter pathways, which bypass
damage, and has been studied as a factor in functional recovery after an ischemic stroke.
There are multiple ways that the brain responds to the injury. One way it compensates for
the damaged tissue is to utilize pathways in the brain that are only activated after the
damage-inducing stroke occurs. There are also new synapses that sprout from fibers of
surviving neurons and create new pathways. Neural routes also exist in the central
nervous system which are typically redundant or parallel in function, and they can replace
the role of some of the broken circuity and retain the function of the lesioned tissue
(Font, Arboix, & Krupinski, 2010; Lee & van Donkelaar, 1995).
Angiogenesis is the formation of new blood vessels. Small microvessels form
after MCAO-induced stroke, and although they prove to be temporary and fragile, they
may be crucial for the removal of necrotic tissue and begin the process of angiogenesis.
Within hours after stroke induction, growth factors that influence angiogenesis (FGF-2,
PDGF, VEGF, and their receptors) are seen in the brain and up-regulated to begin the
growth of new blood vessels. Within five to seven days, fully functioning vessels are
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present (Font et al., 2010; Xiong, Mahmood, & Chopp, 2010). These new blood vessels
also aid in neurogenesis because they deliver the nutrients and support for their survival.
This same increase in angiogenesis may have also led to the secondary
hemorrhagic stroke in the drug-treated animals discussed previously. Vascular
endothelial growth factor (VEGF) is a growth factor associated with angiogenesis and the
increased permeability of blood vessels. This is very important during repair and
neurogenesis because it allows for the delivery of essential restoration components after
ischemic stroke (Duffy, Bouchier-Hayes, & Harmey, 2000; Z. G. Zhang et al., 2000). It
has been found in previous studies that fluoxetine and simvastatin increase levels of
VEGF (Chen et al., 2003, 2005; Warner-Schmidt & Duman, 2007), but in some cases this
is not always beneficial.
A study conducted in 2000, found that early administration of VEGF did not
result in the typical positive result of angiogenesis to the repair of damaged tissue. When
administered 1-hour after stroke, it caused excess permeability to the blood vessels in the
surrounding area and led to collapse of the vessels and hemorrhaging (Z. G. Zhang et al.,
2000). This is the most probable reason for our secondary hemorrhagic damage in our
FS-treated rats. The VEGF levels were so high, the newly formed blood vessels became
too permeable, and their structures collapsed, leading to blood leaking into the brain and
creating additional damaged tissue.
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Rehabilitation
It should also be noted that as part of another study, the same rats in this paper
were also given rehabilitation to study its effects on recovery. It has been studied
previously that the voluntary forced rehabilitation after stroke has yielded a significant
increase in functional recovery (Livingston-Thomas, McGuire, Doucette, & Tasker,
2014), but rehabilitation was shown to not have a significant effect on functional
recovery results when comparing all the control animals to all the drug-treated animals in
our particular study. Only rats not given any treatment at all (neither rehabilitation nor the
simvastatin and fluoxetine drug combination) displayed a significantly lower functional
recovery. This means that rehabilitation did not increase functional recovery (Ragas et
al., 2015). We had hoped to see increased functional recovery correlated with the
increased production of new neurons; however, we saw no correlation between the two.
Drug treatment did not produce significant increases in neurogenesis nor did it translate
to an increase in functional recovery.

Stroke-Induced Neurogenesis
While there was no correlation between an functional recovery and neurogenesis,
we found a significantly higher amount of neurogenesis in the right hemisphere of the
anterior and middle subventricular zone in the drug treated animals when we analyzed
them separately from the control group. These findings suggest that the increase in
neurogenesis was not just from the stroke induction itself, which can cause an increase in
production of neurons at the site of trauma (Lichtenwalner & Parent, 2006).
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Another possibility could be that the drug dosage was insufficient to create a
quantifiable difference in neurogenesis when compared to the control group. Previous
work showed that fluoxetine treatment increased neurogenesis but it did not translate to
functional recovery (X. Sun et al., 2015; Windle & Corbett, 2005). This may have been
what happened in our study as well, but it is difficult to compare the two studies due to
the administration of the drug treatment. We administered our drug combination via
cookie dough to lower stress while Sun, et al. used an implanted pump, which may have
caused additional stress to the animals. To look further into this aspect, the experiment
needs to be repeated, to see if the drug dosage needs to be altered.

Prolonged Fluoxetine
There is another possible explanation for the lack of evidence of a significant
increase in neurogenesis between the drug-treated group and the control group. It has
been shown that prolonged administration of fluoxetine may decrease the growth of new
neurons. A study in 2011 found that chronic treatment with fluoxetine for more than 6
weeks decreased neurogenesis in the subventricular zone of adult mice (Ohira &
Miyakawa, 2011). Our study lasted a duration of 90 days, which exceeds the length of
time they found to show a decrease in neurogenesis. They had some distinct differences
in their study; the use of mice instead of rats and the dosage of fluoxetine. Their dosage
of fluoxetine was 15mg/kg, while we chose a lower dosage of 5mg/kg.
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FUTURE WORK
The research conducted for this thesis provided us with some confounding
information, and it has raised some questions on how to proceed from this point. There is
promise for some answers to these questions with more experimentation.

Repeat Study
There were multiple issues that could be resolved if these experiments were
repeated. The elements of the drug treated group, rehabilitation, increasing the number of
animals in the study, and monitoring neurogenesis are all variables that could give clearer
results, if altered.

Changes to the Drug Treatment
A previous study was conducted in our lab which showed that the drug
combination chosen for this study resulted in the highest increase in functional recovery
after ischemic stroke (A. M. Corbett et al., 2015). Repeated research would yield more
information on the best time, dosage, and duration of the FS drug combination.

Time of Drug Delivery

We saw a larger functional deficit in the drug-treated animals and this is most
likely due to the early delivery (between 6-12 hours after stroke induction) of the drug
combination causing a secondary hemorrhagic stroke which was observed in a parallel
study and seen in Figure 13 (Balch et al., 2015). A later administration of the drug
treatment of 20-26 hours was tested previously without the observation of additional
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damage to the animal (A. M. Corbett et al., 2015). This is the most crucial change to the
methods of this research when repeating because of the additional damage to the neural
tissue and the resulting functional deficits it invoked.

Alter the Drug Dosages

There have not been additional experiments conducted that alter the dosage
amounts for each drug in the combination. It would be extremely beneficial to repeat this
study and try multiple variations of dosage combinations to see which one yields the
highest increase in not only functional recovery but also neurogenesis.

Duration of Drug Treatment

Once the drug combination factor is determined, it would be beneficial to
reproduce this work with different duration times to see which produces the optimal
results. Based on the findings from a study which found that chronic fluoxetine treatment
of 6 weeks decreased neurogenesis (Ohira & Miyakawa, 2011), it would be interesting to
see how the duration of drug administration would affect functional recovery as well as
neurogenesis. This is a key element to resolve for the treatment of human patients,
especially if chronic treatment after a certain amount of time proves to be detrimental to
the patient as opposed to being beneficial.

Removal of Rehabilitation Component
It would also be advantageous to take out the rehabilitation factor when repeating
this work. It added a component to the experiment that did not show any benefit when
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conducted with a drug. It may have also confounded the results by adding a variable,
which was hard to account for when trying to quantify the effect of a drug treatment on
neurogenesis.

Increase Number of Animals
We had a total of 22 rats (11 control and 11 FS-treated) in this study and some of
our results yielded a high amount of error due to a couple of outlying data points. When
your sample size is this low, a couple of outliers increase the error drastically and
decrease the chance of getting data with a significant p-value. A clearer picture of the
significance of drug treatment on neurogenesis would be seen with an increase in sample
size.

Monitor Neurogenesis
There are limited ways to quantify neurogenesis at the moment. There is no
neuroimaging software or functional test to calculate the amount of neurogenesis without
euthanizing the rat. The best way to monitor neurogenesis would be to repeat the research
conducted in this study and euthanize at different intervals. This will tell us when
neurogenesis is at its highest. It will also help us find the best window of time for drug
administration to give us peak neurogenesis and functional recovery results.
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CONCLUSIONS
This study did not find a correlation between functional recovery and increased
neurogenesis. Though we saw no significance increase in the contralateral functional
recovery of drug-treated animals, there was significantly more neurogenesis in the right
hemisphere in the anterior and middle region of the SVZ of the FS rats. This tells us that
the drug treatment did produce a significant amount of neurogenesis at the site of
damage, but further work needs to be done to see if an alteration of the drugs
administered can produce a significance from the control group as well.
The secondary hemorrhagic stroke caused by the early administration of the drugs
may have confounded some of the findings of this study. The secondary stroke most
likely led to the contralateral functional recovery being significantly lower for the drugtreated group than the control. The drug treated group did show a higher total recovery,
which means that without the initial damage of the secondary stroke to repair; they may
have displayed significantly higher contralateral functional recovery from the beginning
of the study.
Further research needs to be conducted to better understand how the fluoxetine
and simvastatin drug treatment affects neurogenesis and functional recovery. There may
be an optimal window of time and dosage that will lead to a greater significance in
recovery and higher levels of neurogenesis. This is key to helping human patients not
only recuperate after experiencing a stroke, but to increase their quality of life after losing
functional capabilities.
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